Selective Enhancement of Nutrient-Induced Insulin Secretion by ATP-Sensitive Kϩ Channel-Blocking Imidazolines

Total Page:16

File Type:pdf, Size:1020Kb

Selective Enhancement of Nutrient-Induced Insulin Secretion by ATP-Sensitive Kϩ Channel-Blocking Imidazolines 0022-3565/09/3313-1033–1041$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 331, No. 3 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 152751/3533565 JPET 331:1033–1041, 2009 Printed in U.S.A. Selective Enhancement of Nutrient-Induced Insulin Secretion by ATP-Sensitive Kϩ Channel-Blocking Imidazolines Kathrin Hatlapatka, Antje Wienbergen, Claudia Ku¨hne, Anne Jo¨rns, Michael Willenborg, and Ingo Rustenbeck Institute of Pharmacology and Toxicology, Technical University of Braunschweig, Braunschweig, Germany (K.H., A.W., C.K., M.W., I.R.); and Institute of Anatomy, Hannover Medical School, Hannover, Germany (A.J.) Received February 27, 2009; accepted September 9, 2009 Downloaded from ABSTRACT ϩ ␮ ␮ The contribution of ATP-sensitive K channel (KATP channel)- M RX871024 or 100 M efaroxan) KATP channel activity was dependent and -independent signaling to the insulinotropic strongly reduced, the membrane was depolarized, and the characteristics of imidazolines was explored using perifused cytosolic Ca2ϩ concentration was elevated in the presence of mouse islets and ␤-cells. Up to a concentration of 100 ␮M basal glucose. Insulin secretion by sulfonylurea receptor efaroxan had no insulinotropic effect in the presence of a basal (SUR)1 knockout (KO) islets, which have no functional KATP jpet.aspetjournals.org glucose concentration, but enhanced the effect of a stimulatory channels, was not increased by efaroxan (100 or 500 ␮M) or by concentration of glucose or nonglucidic nutrients (ketoisocap- 10 ␮M RX871024 but was increased by 100 ␮M RX871024. The roate plus glutamine). The secretion by a non-nutrient (40 mM imidazolines phentolamine and alinidine (100 ␮M) were also KCl) was not enhanced. At 500 ␮M, efaroxan stimulated insulin ineffective on SUR1 KO islets. It is concluded that a significant ␮ secretion when glucose was basal. Likewise, at 0.1 to 10 M KATP channel block is compatible with a purely enhancing RX871024 [2-(imidazolin-2-yl)-1-phenylindole] showed a purely effect of the imidazolines on nutrient-induced insulin secretion. enhancing effect, but at 100 ␮M it elicited a strong KCl-like Only RX871024 has an additional, nondepolarizing effect, at ASPET Journals on March 10, 2015 secretory response in the presence of basal glucose. At 0.1 and which at a high drug concentration is able to elicit a KATP 1 ␮M RX871024 did not significantly depolarize the ␤-cell mem- channel-independent secretion. brane. However, at a purely enhancing drug concentration (10 The insulinotropic effect of the prototypical imidazoline ing occurs with nanomolar affinity, binding to I3 sites re- phentolamine was originally believed to be due to an antag- quires micromolar concentrations of the imidazoline (Rust- ␣ ␤ onism at 2-adrenoceptors of the -cell (Robertson and Porte, enbeck et al., 1997). 1973; Efendic et al., 1975). The observation that the insuli- The demonstration that phentolamine and other imidazo- notropic effect of this compound was not shared by other lines block ATP-sensitive Kϩ channels (K channels) in ␣ ATP antagonists at 2-adrenoceptors but was shared by other pancreatic ␤-cells offered an explanation for their insulino- compounds with imidazoline moieties (Ostenson et al., 1988; tropic property (Plant and Henquin, 1990; Chan and Morgan, Schulz and Hasselblatt, 1989) led to the hypothesis that the 1990). However, it remained unclear how the effect on the insulinotropic effect was mediated by a ␤-cell-specific sub- KATP channel was related to the nonadrenergic imidazoline type of the imidazoline receptor (Chan et al., 1994). In other binding sites on ␤-cells (Rustenbeck et al., 1997). The concept tissues, at least two nonadrenergic imidazoline binding sites of a ␤-cell imidazoline receptor mediating multiple effects by have been identified, and consequently the hypothetical signal transduction cascades was rendered less likely by the ␤-cell subtype was named I receptor (Eglen et al., 1998; 3 observation that the K channel block by imidazolines was Morgan, 1999). In contrast to the I and I sites where bind- ATP 1 2 exerted directly at Kir6.2, the pore-forming subunit of the channel (Proks and Ashcroft, 1997; Grosse-Lackmann et al., This work was supported by grants from the Deutsche Forschungsgemein- 2003). Kir6.2 was then suggested to be the correlate of the I3 schaft [Ru 368/4-1, Ru 368/5-1]; and by the German Diabetes Society. receptor (Monks et al., 1999; Morgan, 1999). Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. The demonstration that the imidazoline RX871024 in- doi:10.1124/jpet.109.152751. creased insulin secretion not only by blocking KATP channels ϩ 2ϩ ABBREVIATIONS: KATP channel, ATP-sensitive K channel; RX871024, 2-(imidazolin-2-yl)-1-phenylindole; [Ca ]c, cytosolic free calcium concentration; BL11282, 5-chlor-3-(imidazolin-2-yl)-2-methylindole; NNC77-0074, (ϩ)-2-(2-(4,5-dihydro-1H-imidazol-2yl)-thiophene-2-yl-ethyl)- pyridine; SUR, sulfonylurea receptor; KO, knockout; KIC, ␣-ketoisocaproic acid; KU14R, 2-(2-ethyl-2,3-dihydrobenzo[b]furan-2-yl)-1H-imidazole. 1033 1034 Hatlapatka et al. ϩ but also by acting at a site distal to Ca2 influx led to the mixing for 1 min. Islets and single islet cells were cultured in cell alternative hypothesis that imidazolines exert effects at mul- culture medium RPMI 1640 with 10% fetal calf serum (5 mM glu- tiple independent sites (Zaitsev et al., 1996). The experimen- cose) in a humidified atmosphere of 95% air and 5% CO2 at 37°C. Electrophysiological Recordings. K channel activity was tal model to demonstrate the KATP channel-independent ef- ATP fect was the permeabilized cell where the cytosolic free measured by a standard patch-clamp technique using the cell-at- 2ϩ 2ϩ tached configuration (Hamill et al., 1981). Pipettes were pulled from calcium concentration ([Ca ]c) was clamped by use of Ca - buffered incubation media. RX871024 (Zaitsev et al., 1996) borosilicate glass (2 mm o.d. and 1.4 mm i.d.; Hilgenberg, Malsfeld, and later efaroxan (Chan et al., 2001) were shown to increase Germany) by a two-stage vertical puller (List Electronics, Darm- stadt, Germany) and had resistances between 3 and 6 M⍀ when insulin release from such permeabilized cell preparations. It filled with solution. Currents were recorded by an EPC 7 patch- was hypothesized that these imidazolines sensitize the exo- 2ϩ clamp amplifier (List Electronics) and low pass-filtered by a four-pole cytotic machinery to [Ca ]c, which in turn would be in- Bessel filter at 2 kHz and stored on a videotape. The pipette holding creased by the KATP channel-blocking effect of these com- potential was 0 mV in cell-attached recordings. The membrane po- pounds. A similar combination of effects, comprising a tential of ␤-cells was determined using the whole-cell and perforated protein kinase C-mediated sensitization of the exocytotic ma- patch modes under current clamp condition (Smith et al., 1990). chinery in addition to a KATP channel block, has been sug- Exposure to the test compounds and washout was done by changing gested to explain the insulinotropic characteristics of sulfo- the bath medium with a slow bath perfusion system. The composi- nylureas (Eliasson et al., 1996). The hypothesis that the tions of the bath and pipette media were as given by Zu¨nkler et al. dependence on stimulatory glucose concentrations is due to (1988). All experiments were performed at room temperature (20– Downloaded from an effect at a site distal to Ca2ϩ influx seemed to be con- 23°C). Data were analyzed off-line using pClamp 6.03 software (Axon firmed by the development of imidazolines (e.g., BL11282 or Instruments, Foster City, CA). Microfluorimetric Measurements of the [Ca2؉] . Islets were NNC77-0074), which do not block KATP channels, but stim- c ulate insulin secretion nevertheless (Efanov et al., 2001b; cultured on collagen-coated glass cover slips in Petri dishes and were Hoy et al., 2003). These imidazolines were then termed “sec- used from days 2 to 4 after isolation. Fura-PE3/AM was loaded at a concentration of 2 ␮M (dissolved in Krebs-Ringer medium with 5 mM ond-generation imidazolines” to distinguish them from the jpet.aspetjournals.org glucose) for 45 min at 37°C. The coverslip with the attached cells or K channel-blocking imidazolines, which were termed ATP islets was inserted in a purpose-made perifusion chamber on the “first-generation imidazolines” (Efendic et al., 2002). stage of an epifluorescence microscope fitted with a Zeiss Fluar (40ϫ) However, a sensitization of the exocytotic machinery to 2ϩ objective. The fluorescence (excitation at 340 or 380 nm; emission [Ca ]c should also amplify subthreshold signals of non-nu- Ͼ470 nm) was recorded by a slow-scan charge-coupled device camera trient secretagogues and thus seems an unlikely explanation (TILL Photonics, Gra¨felfing, Germany). All perifusions were per- for the selective enhancement by efaroxan and RX871024 of formed at 35°C using a HEPES-buffered Krebs-Ringer-bicarbonate the effect of suprathreshold glucose concentrations (Zaitsev medium. Image pairs were taken at intervals as indicated in the at ASPET Journals on March 10, 2015 et al., 1996; Efendic et al., 2002; Bleck et al., 2004). In this figures; illumination time for each image was 800 ms. RX871024, but study, we present evidence that the selective enhancement not efaroxan, proved to be fluorescent with an excitation maximum 2ϩ does not consist of a sensitization of exocytosis to [Ca ]c at 331 nm and a broad emission peak with a maximum at 460 nm. increases but of an enhanced efficacy of amplifying signals This necessitated performing the experiments in duplicate using derived from the metabolism of suprathreshold concentra- sham-loaded islets to subtract the RX871024 fluorescence from the tions of nutrient secretagogues (Henquin, 2000). Despite this Fura fluorescence emission.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Master.Pmd 2
    The Effects of Idazoxan and Efaroxan Improves Memory and Cognitive Functions in Rats Experimental research GABRIELA RUSU-ZOTA1, DANIEL VASILE TIMOFTE2*, ELENA ALBU1, PETRONELA NECHITA3, VICTORITA SORODOC4 1 Grigore T. Popa University of Medicine and Pharmacy, Department of Pharmacology, Clinical Pharmacology and Algesiology, 16 Universitatii Str., 700115, Iasi, Romania 2 Grigore T. Popa University of Medicine and Pharmacy, Department of Surgery, 16 Universitatii Str., 700115, Iasi, Romania 3 Institutul de psihiatrie Socola, Soseaua Bucium, nr 36, 700282, Iasi, Romania 4 Grigore T. Popa University of Medicine and Pharmacy, Department of Internal Medicine, 16 Universitatii Str., 700115, Iasi, Romania Investigating the effects of idazoxan and efaroxan imidazoline receptor antagonists on cognitive functions with the rat Y-maze test; an internationally recognized experimental pattern of behavior, is to be used in order to evaluate the effects of test substances on the simple spatial memory of the laboratory animals. Our experimental evaluation tested the influence induced by idazoxan and efaroxan on the short-term memory on rats. In the experiment were used eighteen (18) male Wistar rats which were randomly divided into three groups (I - Control, II - IDZ and III - EFR) comprising of 6 animals each, treated intraperitoneally according to the following protocol: group I (Control): distilled water 0.5 mL/100 g body weight; group II (IDZ): idazoxan 3 mg/kg body weight; group III (EFR): efaroxan 1 mg/kg body weight. The purpose of this research was to assess the eligibility using the Y-maze test, involving: latency of the first arm visited, the number of arms visited, and the time spent into the arms, the number of returns of the experimental animals in the same arm, the number of alternations, percentage of spontaneous alternation.
    [Show full text]
  • Original Article Dexmedetomidine Inhibits Epileptiform Activity in Rat Hippocampal Slices
    Int J Clin Exp Med 2017;10(4):6704-6711 www.ijcem.com /ISSN:1940-5901/IJCEM0046980 Original Article Dexmedetomidine inhibits epileptiform activity in rat hippocampal slices Atsushi Kurosawa, Yasumitsu Sato, Tomoki Sasakawa, Takayuki Kunisawa, Hiroshi Iwasaki Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan Received December 20, 2016; Accepted January 23, 2017; Epub April 15, 2017; Published April 30, 2017 Abstract: Purpose: Our study aimed to investigate the effects of dexmedetomidine on basal synaptic transmission in the rat hippocampus. We also examined dexmedetomidine in an animal epilepsy model, with further investigation into the role of specific antagonists on the alpha-2 adrenoceptors and the imidazoline receptors. Methods: All of the experiments used the CA1 region of hippocampal brain slices prepared from Sprague-Dawley rats. Epileptiform discharges were induced by perfusing Mg2+-free artificial cerebrospinal fluid (ACSF). We first investigated the ef- fects of dexmedetomidine on population spike (PS) amplitudes and field excitatory postsynaptic potentials (fEPSP) amplitudes in normal ACSF. We then investigated the effects of dexmedetomidine on the amplitudes of the first three PSs and the discharge duration in Mg2+-free ACSF or in normal ACSF containing 10 μM bicuculline. Results: Dexmedetomidine depressed PS amplitudes and fEPSP without affecting the paired-pulse inhibition in normal ACSF. Dexmedetomidine inhibited the epileptiform activity produced by Mg2+-free ACSF in a dose-dependent manner. Dexmedetomidine completely abolished the epileptiform activity induced by bicuculline. In the presence of yohim- bine, dexmedetomidine had no significant effect on epileptiform activity. In the presence of efaroxan and idazoxan, dexmedetomidine significantly (P < 0.05) increased and slightly attenuated the amplitude of the epileptiform activ- ity, respectively.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • JPET #87510 Title: MAPK PHOSPHORYLATION in THE
    JPET Fast Forward. Published on May 18, 2005 as DOI: 10.1124/jpet.105.087510 JPETThis Fast article Forward. has not been Published copyedited andon formatted. May 18, The 2005 final asversion DOI:10.1124/jpet.105.087510 may differ from this version. JPET #87510 Title: MAPK PHOSPHORYLATION IN THE ROSTRAL VENTROLATERAL MEDULLA PLAYS A KEY ROLE IN IMIDAZOLINE (I1) RECEPTOR MEDIATED HYPOTENSION Jian Zhang and Abdel A. Abdel-Rahman Department of Pharmacology and Toxicology Downloaded from Brody School of Medicine East Carolina University jpet.aspetjournals.org Greenville, NC 27834 (ARA and JJ) Tel: (252) 744-3470, FAX: (252) 744-3203 E-mail: [email protected] at ASPET Journals on September 25, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on May 18, 2005 as DOI: 10.1124/jpet.105.087510 This article has not been copyedited and formatted. The final version may differ from this version. JPET #87510 Running title: RVLM MAPKp42/44 contributes to I1-receptor mediated hypotension Abdel A. Abdel-Rahman Department of Pharmacology and Toxicology, Brody School of Medicine East Carolina University, Greenville, NC 27834 Tel: (252) 744-3470, FAX: (252) 744-3203 E-mail: [email protected] Downloaded from Document statistics: Text pages: 27 jpet.aspetjournals.org Number of figures: 7 Number of tables: 1 Number of references: 26 at ASPET Journals on September 25, 2021 Abstract: 201 words Introduction: 490 words Discussion: 1389 words Abbreviations: α-methylnorepinephrine (α-MNE) Artificial cerebrospinal fluid (ACSF) Mitogen-activated protein kinase (MAPK) Nucleus tractus solitarius (NTS) Phosphatidylcholine-specific phospholipase C (PC-PLC) Rostral ventrolateral medulla (RVLM) 2 JPET Fast Forward.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,107,917 B2 Wan 45) Date of Patent: Aug
    US009 107.917B2 (12) United States Patent (10) Patent No.: US 9,107,917 B2 Wan 45) Date of Patent: Aug. 18,9 2015 (54) TREATMENT OF SEPSIS AND (56) References Cited INFLAMMATION WITH ALPHA ADRENERGIC ANTAGONSTS U.S. PATENT DOCUMENTS 5,069,911 A 12/1991 Zuger (75) Inventor: Ping Wang, Roslyn, NY (US) 5,661,172 A 8/1997 Colpaert et al. 5,674,836 A * 10/1997 Kilbournet al. ............... 514/24 6,472,181 B1 10/2002 Mineau-Hanschke ....... 435,703 (73) Assignee: The Feinstein Institute For Medical 6,489,296 B1 * 12/2002 °N ke 424/94.64 Research, Manhasset, NY (US) 6,514,934 B1* 2/2003 Garvey et al. ................ 514, 20.6 2005.0049256 A1 3, 2005 Lorton et al. (*) Notice subsists listing FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 1520 days. EP 1086695 A1 3f2001 (21) Appl. No.: 11/920,309 OTHER PUBLICATIONS Maestroni, J of Neuroimmunology 144, 2003, 91-99.* 22) PCT Fled: Mayy 11, 2006 Remington's Pharmaceutical Sciences, 1980, Sixteenth Edition, p. 420-425. (86). PCT No.: PCT/US2006/0187.17 Wenzel et al (Clinical Infectious Disease, 1996, 22, 407-13).* Rao (Intensive Care Med, 1998, 283-285).* S371 (c)(1), Rascol (Movement Disorders, 16, 4, 2001).* (2), (4) Date: Dec. 15, 2008 Yang et al. (Am J of Physiol Gastrointest Liver Physiology G1014 G1021, 2001).* Yohimbe (American Cancer Society, Yohimbe, 2008).* (87) PCT Pub. No.: WO2006/124770 Kearney (Ann Pharmacotherapy 2010, p. 1-2).* PCT Pub. Date: Nov. 23, 2006 Zhou et al (Biochimica Biophysica Acta, 1537, 2001, 49-57).* Merck, 2008, Sepsis and Septic Shock.* (65) Prior Publication Data Sepsis (http://my.clevelandclinic.org/health/diseases conditions/ hic Sepsis, 2011).* US 2009/O2O2S18A1 Aug.
    [Show full text]
  • Imidazoline Receptor
    Imidazoline Receptor Imidazoline receptors are the primary receptors on which clonidine and other imidazolines act. There are three classes of imidazoline receptors: I1 receptor – mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure, (NISCH or IRAS, imidazoline receptor antisera selected), I2 receptor - an allosteric binding site of monoamine oxidase and is involved in pain modulation and neuroprotection, I3 receptor - regulates insulin secretion from pancreatic beta cells. Activated I1-imidazoline receptors trigger the hydrolysis of phosphatidylcholine into DAG. Elevated DAG levels in turn trigger the synthesis of second messengers arachidonic acid and downstreameicosanoids. In addition, the sodium-hydrogen antiporter is inhibited, and enzymes of catecholamine synthesis are induced. The I1-imidazoline receptor may belong to the neurocytokine receptorfamily, since its signaling pathways are similar to those of interleukins. www.MedChemExpress.com 1 Imidazoline Receptor Agonists, Inhibitors & Antagonists Agmatine sulfate Allantoin Cat. No.: HY-101238 (5-Ureidohydantoin) Cat. No.: HY-N0543 Agmatine sulfate exerts modulatory action at Allantoin is a skin conditioning agent that multiple molecular targets, such as promotes healthy skin, stimulates new and healthy neurotransmitter systems, ion channels and nitric tissue growth. oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor. Purity: ≥98.0% Purity: 99.85% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g Size: 10 mM × 1 mL, 100 mg Efaroxan hydrochloride Harmane Cat. No.: HY-B1416A Cat. No.: HY-101392 Efaroxan hydrochloride is a potent, selective and Harmane, a β-Carboline alkaloid (BCA), is a potent orally active α2-adrenoceptor antagonist, with neurotoxin that causes severe action tremors and antidiabetic activity.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Effects of Two Imidazoline Receptor Antagonists in Spontaneous Behaviour in Rats
    FARMACIA, 2015, Vol. 63, 2 ORIGINAL ARTICLE EFFECTS OF TWO IMIDAZOLINE RECEPTOR ANTAGONISTS IN SPONTANEOUS BEHAVIOUR IN RATS GABRIELA RUSU1, CATALINA ELENA LUPUSORU1*, LILIANA MITITELU TARTAU1, GRATIELA POPA2, NELA BIBIRE3, RAOUL VASILE LUPUSORU4, ANA-CATERINA CRISTOFOR1, MIHAI NECHIFOR1 1University of Medicine and Pharmacy ‘Grigore T. Popa’, Faculty of Medicine, Department of Pharmacology-Algesiology, Universitatii St. no. 16, code 700115, Iasi, Romania 2University of Medicine and Pharmacy ‘Grigore T. Popa’, Faculty of Pharmacy, Department of Pharmaceutical Technology, Universitatii St. no. 16, code 700115, Iasi, Romania 3University of Medicine and Pharmacy ‘Grigore T. Popa’, Faculty of Pharmacy, Department of Analytical Chemistry, Universitatii St. no. 16, code 700115, Iasi, Romania 4University of Medicine and Pharmacy ‘Grigore T. Popa’, Faculty of Medicine, Department of Patho-Physiology, Universitatii St. no. 16, code 700115, Iasi, Romania *corresponding author: [email protected] Manuscript received: September 2014 Abstract We aimed to investigate the effects of imidazoline receptor antagonists’ idazoxan and efaroxan on spontaneous behaviour in rats. Rats were treated intraperitoneally with single doses of either idazoxan (1 mg/kgbw) and efaroxan (3 mg/kgbw) or distilled water (0.3 mL/ 100 g body weight). Locomotor activity and exploratory behaviour of the animals were evaluated using the LE-8811 Actimeter PanLAB device in order to count the number of horizontal, vertical and stereotypic movements. The data were presented as mean ± standard deviation, statistical significance being calculated using the ANOVA test of the SPSS 17.00 Statistics software. Intraperitoneal administration of idazoxan and efaroxan resulted in a reduction of rat horizontal, vertical and stereotypic movements, statistically significant compared to control group.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]